.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
QuintilesIMS
Fuji
Federal Trade Commission
Covington
Chubb
Cipla
Moodys
Medtronic
Dow

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,608,698

« Back to Dashboard

Which drugs does patent 8,608,698 protect, and when does it expire?


Patent 8,608,698 protects AUVI-Q and EVZIO and is included in three NDAs.

This patent has one hundred patent family members in fourteen countries.

Summary for Patent: 8,608,698

Title:Devices, systems and methods for medicament delivery
Abstract: An apparatus includes a housing, a needle, a first energy storage member and a second energy storage member. The needle is movably disposed within the housing and is configured to be to be placed in fluid communication with a medicament container. The needle is configured to move between a first position and a second position. In its first position, the needle is contained within the housing. In its second position, at least a portion of the needle extends from the housing. The first energy storage member is disposed within the housing, and is configured to produce a first force when actuated. The second energy storage member is disposed within the housing, and is configured to be actuated in response to the first force to produce a second force to move the needle from the first needle position to the second needle position.
Inventor(s): Edwards; Eric Shawn (Midlothian, VA), Edwards; Evan Thomas (Fredericksburg, VA), Licata; Mark J. (Doswell, VA), Meyers; Paul F. (Fishers, IN)
Assignee: Intelliject, Inc. (Richmond, VA)
Application Number:13/053,451
Patent Claim Types:
see list of patent claims
Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Kaleo IncAUVI-QepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS201739-002Aug 10, 2012BXRXYesYes► Subscribe► SubscribeY► Subscribe
Kaleo IncAUVI-QepinephrineINJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS201739-001Aug 10, 2012BXRXYesNo► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS205787-001Apr 3, 2014DISCNYesNo► Subscribe► SubscribeY► Subscribe
Kaleo IncEVZIOnaloxone hydrochlorideSOLUTION;INTRAMUSCULAR, SUBCUTANEOUS209862-001Oct 19, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,608,698

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,361,029Devices, systems and methods for medicament delivery► Subscribe
8,313,466Devices, systems and methods for medicament delivery► Subscribe
7,918,823Devices, systems and methods for medicament delivery► Subscribe
8,544,645Devices, systems and methods for medicament delivery► Subscribe
9,278,182Devices, systems and methods for medicament delivery► Subscribe
9,327,077Medical injector with compliance tracking and monitoring► Subscribe
8,226,610Medical injector with compliance tracking and monitoring► Subscribe
9,278,177Medical injector with compliance tracking and monitoring► Subscribe
9,259,539Devices, systems and methods for medicament delivery► Subscribe
8,123,719Devices, systems and methods for medicament delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,608,698

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2012201481► Subscribe
Australia2015264857► Subscribe
Canada2586525► Subscribe
Canada2594627► Subscribe
Canada2644547► Subscribe
United Kingdom2478085► Subscribe
Canada2669616► Subscribe
Canada2724069► Subscribe
Canada2743303► Subscribe
Canada2762072► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Mallinckrodt
Fish and Richardson
Covington
Teva
Chinese Patent Office
Cerilliant
Farmers Insurance
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot